We are live on ! Find out more
DYN icon

Dyne Therapeutics
DYN

124 hedge funds and large institutions have $957M invested in Dyne Therapeutics in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

176% more call options, than puts

Call options by funds: $16M | Put options by funds: $5.78M

79% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 14

78% more capital invested

Capital invested by funds: $537M → $957M (+$420M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

19.06% more ownership

Funds ownership: 98.15% → 117.21% (+19%)

9% more funds holding

Funds holding: 114 → 124 (+10)

8% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 40

Holders
124
Holders Change
+10
Holders Change %
+8.77%
% of All Funds
1.81%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
25
Increased
43
Reduced
40
Closed
14
Calls
$16M
Puts
$5.78M
Net Calls
+$10.2M
Net Calls Change
+$7.22M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$38.4M
2
FLSM
Frazier Life Sciences Management
California
+$11.6M
3
CC
Commodore Capital
New York
+$8.79M
4
BlackRock
BlackRock
New York
+$4.71M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.26M

Top Sellers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
-$10.4M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$4.25M
3
DTC
Deep Track Capital
Connecticut
-$3.94M
4
AC
Armistice Capital
New York
-$3.67M
5
Goldman Sachs
Goldman Sachs
New York
-$3.39M
Name Holding Trade Value Shares
Change 		Change in
Stake
OCA
26
Octagon Capital Advisors
New York
$10.5M +$977K +100,000 +14%
CS
27
Candriam SCA
Luxembourg
$10.2M +$391K +40,000 +6%
B
28
Braidwell
Connecticut
$10.1M -$10.4M -1,066,161 -59%
NCM
29
Nantahala Capital Management
Connecticut
$8.55M -$394K -40,375 -6%
Axa
30
Axa
France
$7.32M +$726K +74,298 +16%
Ensign Peak Advisors
31
Ensign Peak Advisors
Utah
$6.8M – – –
WP
32
Woodline Partners
California
$5.79M +$973K +99,642 +30%
Northern Trust
33
Northern Trust
Illinois
$5.63M +$282K +28,834 +7%
LCM
34
Laurion Capital Management
New York
$5.32M +$3.91M +400,000 New
Point72 Asset Management
35
Point72 Asset Management
Connecticut
$5.18M -$1.82M -186,600 -32%
Millennium Management
36
Millennium Management
New York
$5.16M +$3.79M +388,090 New
ACH
37
ArrowMark Colorado Holdings
Colorado
$5.09M – – –
Federated Hermes
38
Federated Hermes
Pennsylvania
$4.99M +$3.66M +375,000 New
Charles Schwab
39
Charles Schwab
California
$4.41M +$60.5K +6,197 +2%
Assenagon Asset Management
40
Assenagon Asset Management
Luxembourg
$3.81M -$4.25M -434,830 -60%
IC
41
Ikarian Capital
Texas
$3.8M +$2.79M +285,900 New
AllianceBernstein
42
AllianceBernstein
Tennessee
$3.73M +$285K +29,128 +12%
SSA
43
Schonfeld Strategic Advisors
New York
$3.67M +$2.69M +275,699 New
Jennison Associates
44
Jennison Associates
New York
$2.7M +$1.98M +202,871 New
CM
45
Caption Management
Oklahoma
$2.49M +$1.83M +187,288 New
Bank of New York Mellon
46
Bank of New York Mellon
New York
$2.27M +$128K +13,117 +8%
Rafferty Asset Management
47
Rafferty Asset Management
New York
$2.18M +$241K +24,632 +18%
AG
48
Algert Global
California
$2.14M +$22.4K +2,291 +1%
Barclays
49
Barclays
United Kingdom
$2.04M +$525K +53,777 +54%
N
50
Nuveen
North Carolina
$2M +$24K +2,453 +2%
1
2
3 4 5

DYN Hedge Fund Activity: Q4 2023 in Review

124 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q4 2023, worth a combined $957M — up 78% from $537M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new DYN positions and 14 closed out — a net gain of 11 holders — while 43 added to existing stakes and 40 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $38.4M. The largest seller was Braidwell, cutting an estimated $10.4M.

  • 124 institutional investors held Dyne Therapeutics (DYN) as of Q4 2023, up from 114 in Q3 2023.
  • Funds reported $957M of Dyne Therapeutics stock for Q4 2023, up 78% quarter-over-quarter.
  • 25 funds opened new Dyne Therapeutics positions in Q4 2023 and 14 closed out, a net change of +11 holders.
  • The largest Dyne Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $38.4M added.
  • The largest Dyne Therapeutics seller in Q4 2023 was Braidwell, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2023.